Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium
Overall Response Rate of 38% Observed in the First 24 Patients Who Had At Least One Scan on Treatment ROCKVILLE, […]
Overall Response Rate of 38% Observed in the First 24 Patients Who Had At Least One Scan on Treatment ROCKVILLE, […]
LEXINGTON, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) — Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing […]
NEWTOWN, Pa., Jan. 22, 2019 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused […]
STAMFORD, Conn., Jan. 22, 2019 (GLOBE NEWSWIRE) — Eagle Bulk Shipping Inc. (NASDAQ: EGLE) (“Eagle” or the “Company”) announced today […]
Publication Highlights Encouraging Evidence of OTL-300’s Safety and Efficacy in Transfusion-Dependent Beta-Thalassemia Patients BOSTON and LONDON, Jan. 22, 2019 (GLOBE […]
RICHMOND, Va., Jan. 22, 2019 (GLOBE NEWSWIRE) — Union Bankshares Corporation (the “Company” or “Union”) (Nasdaq: UBSH) today reported net […]
Six Minute Walk Test Acceptable as Primary Efficacy Endpoint for Potential Registration Program SOUTH SAN FRANCISCO, Calif., Jan. 22, 2019 […]
Breakthrough Therapy Designation granted based on interim data from the Marginal Zone Lymphoma cohort of the UNITY-NHL trial NEW YORK, […]
ATHENS, Greece, Jan. 22, 2019 (GLOBE NEWSWIRE) — TOP Ships Inc. (the “Company”), an international owner and operator of modern, […]
WINTER SPRINGS, Fla., Jan. 22, 2019 (GLOBE NEWSWIRE) — IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its […]